Gilman Steven C
Former Director at VCEL; Director at AKBA; Director at MOMENTA PHARMACEUTICALS INC, and 2 more
- Sold, on record
- $17.6M
- Dollars the filings state
- Form 4 sales
- 38
- Latest Oct 16, 2024
- Form 144 notices
- 5
- Proposed sales
- Companies
- 5
- Filed as an executive or holder
Companies
- VCELVericel CorpFormer Director
- AKBAAkebia Therapeutics, Inc.Director
- MOMENTA PHARMACEUTICALS INCDirector
- KERYX BIOPHARMACEUTICALS INCDirector
- CUBIST PHARMACEUTICALS INCEVP & Chief Scientific Officer
Sales by reason
Form 4 sales per year, every sale on record.
Sales by company
- CUBIST PHARMACEUTICALS INC264,143 shares
- VCEL70,900 shares
- MOMENTA PHARMACEUTICALS INC35,294 shares
- AKBA13,701 shares
- KERYX BIOPHARMACEUTICALS INC2,667 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale VCELRoutineSep 4, 2024 2024
Sold 5,000 shares at $48.58 ($243k)
Gilman Steven C, Director
10b5-1 planSold 31.3% of holdings ($777k position)11,000 shares leftFirst sale on recordFollows a Form 144Filing
- 2 Form 144 notice VCELNoticeSep 18, 2024 +14 days
Filed to sell 5,834 shares ($266k)
Gilman Steven C, Director
10b5-1 planFiling
- 3 Form 4 sale VCELRoutineSep 18, 2024 same day
Sold 5,834 shares at $45.54 ($266k)
Gilman Steven C, Director
10b5-1 planSold 34.7% of holdings ($767k position)11,000 shares leftFollows a Form 144Filing
- 4 Form 144 notice VCELNoticeOct 2, 2024 +14 days
Filed to sell 5,833 shares ($235k)
Gilman Steven C, Director
10b5-1 planFiling
- 5 Form 4 sale VCELRoutineOct 2, 2024 same day
Sold 5,833 shares at $40.35 ($235k)
Gilman Steven C, Director
10b5-1 planSold 34.7% of holdings ($679k position)11,000 shares leftFollows a Form 144Filing
- 6 Form 144 notice VCELNoticeOct 16, 2024 +14 days
Filed to sell 5,833 shares ($241k)
Gilman Steven C, Director
10b5-1 plan1x usual sizeFiling
- 7 Form 4 sale VCELRoutineOct 16, 2024 same day
Sold 5,833 shares at $41.36 ($241k)
Gilman Steven C, Director
10b5-1 planSold 34.7% of holdings ($696k position)11,000 shares left1x usual sizeFollows a Form 144Filing
- 8 Form 144 notice VCELNoticeMay 30, 2025 +226 days
Filed to sell 13,125 shares ($551k)
Gilman Steven C, Former Director
No 10b5-1 plan2.3x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (43)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| May 30, 2025 | May 30, 2025 | VCEL | Former Director | Form 144 notice | 13,125 | $551k | Notice | SEC | |
| Oct 16, 2024 | Oct 18, 2024 | VCEL | Director | Form 4 sale | 5,833 | $241k | 34.7% | Routine | SEC |
| Oct 16, 2024 | Oct 16, 2024 | VCEL | Director | Form 144 notice | 5,833 | $241k | Notice | SEC | |
| Oct 2, 2024 | Oct 4, 2024 | VCEL | Director | Form 4 sale | 5,833 | $235k | 34.7% | Routine | SEC |
| Oct 2, 2024 | Oct 2, 2024 | VCEL | Director | Form 144 notice | 5,833 | $235k | Notice | SEC | |
| Sep 18, 2024 | Sep 20, 2024 | VCEL | Director | Form 4 sale | 5,834 | $266k | 34.7% | Routine | SEC |
| Sep 18, 2024 | Sep 18, 2024 | VCEL | Director | Form 144 notice | 5,834 | $266k | Notice | SEC | |
| Sep 4, 2024 | Sep 5, 2024 | VCEL | Director | Form 4 sale | 5,000 | $243k | 31.3% | Routine | SEC |
| Sep 4, 2024 | Sep 4, 2024 | VCEL | Director | Form 144 notice | 5,000 | $245k | Notice | SEC | |
| Jun 3, 2022 | Jun 7, 2022 | AKBA | Director | Form 4 sale | 4,567 | $2k | 9.5% | Plan not stated | SEC |
| Apr 29, 2022 | May 2, 2022 | VCEL | Director | Form 4 sale | 900 | $28k | 14.8% | Plan not stated | SEC |
| Nov 29, 2021 | Dec 1, 2021 | VCEL | Director | Form 4 sale | 5,000 | $196k | 58.8% | Unusual | SEC |
| Oct 27, 2021 | Oct 28, 2021 | VCEL | Director | Form 4 sale | 5,000 | $253k | 58.8% | Unusual | SEC |
| Sep 30, 2021 | Oct 1, 2021 | VCEL | Director | Form 4 sale | 5,000 | $244k | 58.8% | Unusual | SEC |
| Jun 7, 2021 | Jun 9, 2021 | AKBA | Director | Form 4 sale | 4,567 | $15k | 8.7% | Plan not stated | SEC |
| Aug 5, 2020 | Aug 7, 2020 | MOMENTA PHARMACEUTICALS INC | Director | Form 4 sale | 13,000 | $426k | 62.5% | Unusual | SEC |
| Jul 29, 2020 | Jul 30, 2020 | MOMENTA PHARMACEUTICALS INC | Director | Form 4 sale | 10,000 | $297k | 56.2% | Unusual | SEC |
| Jul 22, 2020 | Jul 23, 2020 | MOMENTA PHARMACEUTICALS INC | Director | Form 4 sale | 10,000 | $332k | 56.2% | Unusual | SEC |
| Jun 8, 2020 | Jun 9, 2020 | AKBA | Director | Form 4 sale | 4,567 | $55k | 10.5% | Plan not stated | SEC |
| May 1, 2019 | May 3, 2019 | VCEL | Director | Form 4 sale | 7,500 | $126k | 100.0% | Unusual | SEC |
| Feb 28, 2019 | Mar 4, 2019 | VCEL | Director | Form 4 sale | 7,500 | $135k | 100.0% | Unusual | SEC |
| Dec 3, 2018 | Dec 4, 2018 | VCEL | Director | Form 4 sale | 8,500 | $151k | 100.0% | Unusual | SEC |
| Sep 4, 2018 | Sep 6, 2018 | VCEL | Director | Form 4 sale | 9,000 | $108k | 100.0% | Unusual | SEC |
| Jun 22, 2018 | Jun 26, 2018 | MOMENTA PHARMACEUTICALS INC | Director | Form 4 sale | 2,294 | $49k | 40.0% | Unusual | SEC |
| Jun 11, 2018 | Jun 12, 2018 | KERYX BIOPHARMACEUTICALS INC | Director | Form 4 sale | 1,334 | $7k | 7.1% | Plan not stated | SEC |
| May 29, 2018 | May 31, 2018 | KERYX BIOPHARMACEUTICALS INC | Director | Form 4 sale | 1,333 | $7k | 6.7% | Plan not stated | SEC |
| Oct 1, 2014 | Oct 2, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 48,125 | $3.1M | 63.6% | Unusual | SEC |
| Jul 28, 2014 | Jul 29, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 40,625 | $2.5M | 59.5% | Unusual | SEC |
| May 15, 2014 | May 15, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 16,340 | $1.1M | 37.2% | Unusual | SEC |
| May 14, 2014 | May 14, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,680 | $116k | 6.0% | Plan not stated | SEC |
| Feb 18, 2014 | Feb 19, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 2,645 | $198k | 9.7% | Plan not stated | SEC |
| Jan 2, 2014 | Jan 2, 2014 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 25,000 | $1.7M | 51.5% | Unusual | SEC |
| Jun 3, 2013 | Jun 3, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 15,125 | $824k | 39.2% | Unusual | SEC |
| May 16, 2013 | May 17, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,201 | $59k | 4.9% | Plan not stated | SEC |
| May 15, 2013 | May 16, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,017 | $49k | 4.4% | Plan not stated | SEC |
| May 14, 2013 | May 15, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,135 | $56k | 5.2% | Plan not stated | SEC |
| Feb 19, 2013 | Feb 20, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,233 | $51k | 6.3% | Plan not stated | SEC |
| Jan 2, 2013 | Jan 3, 2013 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 15,000 | $645k | 48.6% | Unusual | SEC |
| May 17, 2012 | May 17, 2012 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 20,000 | $831k | 52.1% | Unusual | SEC |
| May 16, 2012 | May 16, 2012 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,597 | $67k | 8.0% | Plan not stated | SEC |
| May 14, 2012 | May 15, 2012 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 1,135 | $47k | 7.0% | Plan not stated | SEC |
| Oct 26, 2011 | Oct 28, 2011 | CUBIST PHARMACEUTICALS INC | EVP & Chief Scientific Officer | Form 4 sale | 71,250 | $2.8M | 85.1% | Unusual | SEC |
| May 17, 2010 | May 18, 2010 | CUBIST PHARMACEUTICALS INC | SVP, Chief Scientific Officer | Form 4 sale | 1,035 | $23k | 15.6% | Plan not stated | SEC |